Key result
Review traces the evolution of DAPT for CAD from early trials to modern practice.
This review provides a comprehensive historical perspective on the development and evolution of dual antiplatelet therapy in the management of coronary artery disease.
Answers are grounded in this paper and cite their sources.
Aids clinician grasp of DAPT evolution; leaves open optimization trials in modern CAD.
Abstract The use of dual antiplatelet therapy (DAPT), defined as a combination of aspirin and an oral P2Y₁₂ inhibitor (ticlopidine, clopidogrel, prasugrel, or ticagrelor), represents one of the key developments in the management of patients with coronary artery disease. In this review article, we provide a historical perspective on the development of DAPT, from the first major trials of DAPT all the way through to the use of DAPT in modern practice. This review encompasses the discovery and development of the 4 oral P2Y₁₂ inhibitors that have progressed to clinical use. This historical overview of DAPT is provided in the context of some of the major developments that have taken place in percutaneous coronary intervention over the past 40 years, alongside a description of the antithrombotic regimens used at the time of these milestones. We finish by providing some personal perspectives on the potential future roles of DAPT in the management of patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Coughlan et al. (2025) conducted a review in Coronary artery disease. Dual antiplatelet therapy (DAPT) was evaluated. This review provides a historical perspective on the development of dual antiplatelet therapy for coronary artery disease, from early trials to modern practice.
Synapse has enriched 10 related papers. Consider them for comparative context: